Six pathways were found to be significantly enriched after Thio-2 treatment; Thio-2 treatment suppressed important pathways implicated in prostate cancer biology including androgen response [normalized enrichment score (NES) −2.43, FDR < 0.01], E2F targets (NES −2.96, FDR < 0.01), G2–M checkpoints (NES −2.59, FDR < 0.01), MYC targets V1 (NES −2.38, FDR < 0.01), and MYC targets V2 (NES −2.14, FDR < 0.01; Fig. 6C and D). Here, MYC is linked to prostate cancer.